Monthly Prescribing Reference

Severe Burn Therapy NexoBrid Gets FDA Approval

Credit: Getty Images. NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has approved ...
Monthly Prescribing Reference

NexoBrid Approval Expanded to Include Pediatric Burn Patients

NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has expanded the approval of ...
Nasdaq

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns YAVNE, Israel, ...
Healio

Botanical drug may outperform standard of care for treatment of severe thermal burns

Please provide your email address to receive an email when new articles are posted on . Phase 3 data shows NexoBrid allows for the early complete eschar removal in more than 90% of patients. This ...
Medscape

Bromelain and Antibiotics Aid Crans-Montana Burn Care

The management of 12 Italian patients with severe burns from a fire on 1 January 2026 at the Crans-Montana ski resort in Switzerland provided a real-world demonstration of emerging strategies for ...
Nasdaq

MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a.m. Eastern time YAVNE, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd.